raloxifene has been researched along with indomethacin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Deguchi, T; Furuta, Y; Fusegawa, K; Hirouchi, M; Igeta, K; Ikenaga, H; Iwasaki, M; Izumi, T; Kurihara, A; Murata, S; Okazaki, O; Suzuki, N; Watanabe, N | 1 |
| Furukawa, T; Hosoya, K; Kadono, K; Moriguchi, H; Nakamori, F; Naritomi, Y; Teramura, T; Terashita, S; Tetsuka, K; Yamano, K | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
2 review(s) available for raloxifene and indomethacin
| Article | Year |
|---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for raloxifene and indomethacin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Area Under Curve; Cytochrome P-450 Enzyme System; Dogs; Drug Evaluation, Preclinical; Glucuronides; Glucuronosyltransferase; Half-Life; Humans; Macaca fascicularis; Male; Mice; Pharmaceutical Preparations; Predictive Value of Tests; Rats; Rats, Sprague-Dawley; Species Specificity | 2011 |
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
Topics: Administration, Oral; Biotransformation; Cell Membrane Permeability; Cytochrome P-450 Enzyme System; Glucuronides; Glucuronosyltransferase; Humans; Intestinal Absorption; Intestines; Isoenzymes; Kinetics; Metabolic Clearance Rate; Microsomes; Models, Biological; Pharmaceutical Preparations; Recombinant Proteins; Substrate Specificity | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |